The EuroSIDA Study
EuroSIDA Prospective Observational Cohort Study on Clinical and Virological Outcome of European Patients Infected With HIV
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование идёт, в реестре указано, что набор участников открыт.
- Возраст участников: от 16 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 23000 чел. во всех странах исследования.
- Центров в реестре: 3 в 2 городах. Список — ниже на странице.
- Плановое окончание — 12.2030.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 2 · невключение: 3
Критерии включения
- HIV-1 infected patients regardless of CD4 cell count and ART status
- Must be positive for antibodies against HCV regardless of HCV-RNA status, fibrosis stage and prior HCV therapy
Критерии невключения
- Patients under 16 years of age
- Already enrolled in EuroSIDA through earlier cohort
- Predefined number of patients has been reached
Источник: ClinicalTrials.gov, NCT02699736 · запись обновлена в реестре 12 апреля 2024.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 9
- Incidence of long-term virological, immunological and morbidity and mortality outcomes across different regions in Europe; and demographic, clinical, therapeutic and viral factors associated with these outcomes — From date of enrollment until the date of progression, lost to follow-up or death, whichever came first, assessed up to 5 years
Цель исследования
The EuroSIDA study is a prospective observational cohort study of 23,000+ patients followed in 100+ clinics in 35 European countries, Israel and Argentina. The study is the largest pan-European cohort study and few studies of a comparable design are available on a global scale. The EuroSIDA study is an ongoing collaboration and patients have been enrolled into the study through 11 cohorts since 1994.
The main objective of the study remains the same as in 1994: to prospectively study, clinical, therapeutic, demographic, virological and laboratory data from HIV-1 positive persons across Europe in order to determine their long-term virological, immunological and clinical outcomes.
Historically, EuroSIDA has been crucial in reporting key changes in the HIV epidemic, such as the dramatic changes in morbidity and mortality when combination anti-retroviral therapy (cART) was first introduced. As new anti-HCV treatment is introduced to HIV/HCV co-infected patients, it is important for EuroSIDA to remain in the forefront of investigating the treatment benefits and adverse effects.
All study documents, study status, newsletters, scientific publications and presentations are available online and are updated continuously at project website.
In general terms, the objective of the EuroSIDA study is to continue a long-term, prospective collection of clinical, laboratory and therapeutic data as well as plasma on a large cohort of consecutive HIV infected patients from across Europe in order to (1) assess the factors associated with the clinical, immunological and virological course of HIV infection and HIV-related co-infections and co-morbidities, and (2) continue to provide and develop a surveillance system to describe temporal changes and regional differences in the clinical course of HIV and HIV-related co-infections and co-morbidities in Europe.
Где проходит
3 центра в 2 городахОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT02699736 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, набор участников, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.